SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-000735
Filing Date
2024-05-10
Accepted
2024-05-10 16:07:31
Documents
54
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20240331x10q.htm   iXBRL 10-Q 595489
2 EX-31.1 enzn-20240331xex31d1.htm EX-31.1 14971
3 EX-32.1 enzn-20240331xex32d1.htm EX-32.1 6381
  Complete submission text file 0001410578-24-000735.txt   2939922

Data Files

Seq Description Document Type Size
4 EX-101.SCH enzn-20240331.xsd EX-101.SCH 32067
5 EX-101.CAL enzn-20240331_cal.xml EX-101.CAL 19324
6 EX-101.DEF enzn-20240331_def.xml EX-101.DEF 99603
7 EX-101.LAB enzn-20240331_lab.xml EX-101.LAB 225325
8 EX-101.PRE enzn-20240331_pre.xml EX-101.PRE 173598
58 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20240331x10q_htm.xml XML 257700
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

IRS No.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 24934884
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)